Conference Coverage
about 1 month ago
Neoadjuvant SAbR shows promising outcomes in RCC with tumor thrombusabout 1 month ago
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBCabout 1 month ago
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBCabout 1 month ago
NDV-01 produces robust 9-month results in high-risk NMIBCLatest News
Jan 13, 2026 | News
RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy
Dosing begins in trial of alpha radioligand therapy for mCRPC
Jan 12, 2026
Trial to evaluate novel combination in BCG-unresponsive NMIBC
Jan 12, 2026
Genomic classifier score linked with focal therapy outcomes in prostate cancer
Jan 09, 2026
Trial to assess testosterone undecanoate in older men with hypogonadism
Jan 09, 2026
Advertisement
Shorts
1:24
Jennifer Miles-Thomas, MD, URPS, MBA, on academic care centers expanding into communities
11 hours ago
by
Jennifer Miles-Thomas, MD, URPS, MBA
1:19
Ridwan I. Alam, MD, MPH, on the PHI test in men with PSA between 10 and 20 ng/mL
a day ago
by
Ridwan I. Alam, MD, MPH
1:08
The Expert APProach: Jennifer Bepple, MD, MMCi, on how APPs enhance patient care
5 days ago
by
Joy Maulik, CRNP
1:07
Bruno Nahar, MD, on the urologic oncology program at Urology on the Beach
6 days ago
by
Bruno Nahar, MD
1:22
The Expert APProach: What Led Jennifer Bepple, MD, MMCi, to Digital Health
7 days ago
by
Joy Maulik, CRNP
1:08
Pearls & Perspectives: Advice for Patients on Disclosing STIs
8 days ago
by
Amy M. Pearlman, MD
1:05
Aleece Fosnight, MSPAS, PA-C, on hormonally mediated bladder symptoms and IC/BPS
9 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:05
Maxwell Sandberg, MD, outlines trial design for study evaluating treatment of RCC with a tumor thrombus
12 days ago
by
Maxwell L. Sandberg, MD
1:16
How an MMAI test can provide reassurance regarding prostate cancer treatment decisions
13 days ago
by
Daniel E. Spratt, MD
1:08
Jesse Mills, MD, on testosterone therapy and cardiovascular health
14 days ago
by
Jesse N. Mills, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.
The phase 2 PROHEAR trial is assessing the safety and efficacy of ACOU085 in preventing ototoxic hearing loss induced by cisplatin-based chemotherapy.
The results from this study are expected to support an application to the FDA for pre-market approval of the Butterfly device.
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
This episode delivers an empowering, forward-looking conversation on how APPs and physicians alike can lead health care transformation.
The study is being conducted as part of the landmark ProtecT trial.
Heidegger emphasizes that sexual concerns are almost never purely biological or purely psychological—they are biopsychosocial.
The code, J9282, went into effect on January 1, 2026.
According to the authors, these findings support the early use of genomic testing to guide treatment decisions.
"Although social media may not be for every health care worker, I hope that moving forward, more medical content creators will collaborate with the academic medical community to shape the world for the better," writes Maheetha Bharadwaj, MD.
Advertisement
A recap of the FDA submissions and regulatory decisions in urology from December 2025.
In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC.
As the year comes to a close, we revisit some of this year’s top content in female urology.
As the year comes to a close, we revisit some of this year’s top content in men's health.
As the year comes to a close, we revisit some of this year’s top content on bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Dosing begins in trial of alpha radioligand therapy for mCRPC
2
Estradiol and ADT: Lessons from Lived Experience
3
High PHI scores are linked to increased odds of significant prostate cancer
4
Mark Tyson, MD, highlights ADVANCED-2 trial in BCG-naïve NMIBC
5